| |
|
|
Il-Yang Pharm. (007570) |
|
|
STOCK |
|
|
| Address |
ILYANG PHARM. CO., 182-4, HAGAL-DONG, GIHEUNG-GU, YONGIN-SI |
| Home Page |
www.ilyang.co.kr
|
| Established |
1971.12.30 |
Tel |
031-281-7851 |
| Listed |
1974. 8.28 |
IR |
02-570-3767 |
| Common shares O/S |
14,102,526 |
President |
Jeong,Do Eon/Kim,Dong Yeon |
| Preferred shares O/S |
445,080 |
No.of Employees |
694(2008. 3) |
| Its sales growth slowed down on weak sales at its beverage business unit. Its profitability weakened on increased costs. It got an approval for its Ilfrazol from China's FDA and a second clinical test for its drug for esophageal inflammation was completed. |
| Sales are expected to increase on sales of its Ilfrazol in South Korea and its global sales. Its business performance is expected to improve on sales of its new drugs such as anticancer drugs. Sales are forecast to be led by increased sales of specialized drugs. |
|
  |
(date: 2007.12, unit : %) |
| Name |
Jeong Doeon |
Jeong Yuseok |
Jeong Hyeongsik |
| Portion |
26.6 |
3.7 |
0.5 |
|
 |
(unit : %) |
| Sales |
DICETEL |
50.9 |
Cost |
Raw Materials |
73.7 |
| Diflucan,etc |
24.5 |
Labors |
8.1 |
| Hitrine |
13.4 |
Overhead |
18.1 |
|
 |
(Unit : 100Mn.Won,Won) |
| Year |
99. 6 |
99.10 |
~00. 3 |
00. 6 |
06. 7 |
| Type |
SD |
RI |
CB |
SD |
SS |
| Amount |
7.50 |
81.60 |
33.08 |
10.09 |
2,500.00 |
|
|
|
|
